Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Zeillinger

Showing results (41-50 of 187) with videos related to

Pageof 19
Sort By:
Journal of the Society for Gynecologic Investigation|January 5, 2005
An interleukin-6 gene promoter polymorphism and unexplained late intrauterine fetal death: a multicenter studyAmbros Huber, Christoph Grimm, Stefan Jirecek, et al.
Metal-Based Drugs|July 10, 2009
In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer AgentUlrike Olszewski, Florian Ach, Ernst Ulsperger, et al.
BMC Cancer|April 11, 2009
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assayVeronika Auner, Gernot Kriegshäuser, Dan Tong, et al.
Investigational New Drugs|October 1, 2021
Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung CancerAdelina Plangger, Barbara Rath, Maximilian Hochmair, et al.
Journal of the Society for Gynecologic Investigation|October 18, 2002
Tumor necrosis factor-alpha promotor polymorphisms and endometriosisFritz Wieser, Gerhild Fabjani, Clemens Tempfer, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|June 5, 2007
The prohibitin 3' untranslated region polymorphism in patients with ovarian cancerChristoph Grimm, Stephan Polterauer, Robert Zeillinger, et al.
Investigational New Drugs|February 18, 2010
Anticancer activity and mode of action of titanocene CUlrike Olszewski, James Claffey, Megan Hogan, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|January 2, 2007
The lack of laminin-5 as a prognostic marker in low-grade cervical squamous intraepithelial lesions: correlation with clinical follow-up dataBarbara Tringler, Christoph Grimm, Grazyna Dudek, et al.
Oncology Reports|February 12, 2005
Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigensNicole I Euer, Sepp Kaul, Helmut Deissler, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 16, 2015
Association of HER2 codon 655 polymorphism with ovarian cancerRafał Watrowski, Dan Cacsire Castillo-Tong, Eva Schuster, et al.
Pageof 19

Showing results (41-50 of 187) with videos related to

Sort By:
Pageof 19
Journal of the Society for Gynecologic Investigation|January 5, 2005
An interleukin-6 gene promoter polymorphism and unexplained late intrauterine fetal death: a multicenter studyAmbros Huber, Christoph Grimm, Stefan Jirecek, et al.
Metal-Based Drugs|July 10, 2009
In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer AgentUlrike Olszewski, Florian Ach, Ernst Ulsperger, et al.
BMC Cancer|April 11, 2009
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assayVeronika Auner, Gernot Kriegshäuser, Dan Tong, et al.
Investigational New Drugs|October 1, 2021
Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung CancerAdelina Plangger, Barbara Rath, Maximilian Hochmair, et al.
Journal of the Society for Gynecologic Investigation|October 18, 2002
Tumor necrosis factor-alpha promotor polymorphisms and endometriosisFritz Wieser, Gerhild Fabjani, Clemens Tempfer, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|June 5, 2007
The prohibitin 3' untranslated region polymorphism in patients with ovarian cancerChristoph Grimm, Stephan Polterauer, Robert Zeillinger, et al.
Investigational New Drugs|February 18, 2010
Anticancer activity and mode of action of titanocene CUlrike Olszewski, James Claffey, Megan Hogan, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|January 2, 2007
The lack of laminin-5 as a prognostic marker in low-grade cervical squamous intraepithelial lesions: correlation with clinical follow-up dataBarbara Tringler, Christoph Grimm, Grazyna Dudek, et al.
Oncology Reports|February 12, 2005
Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigensNicole I Euer, Sepp Kaul, Helmut Deissler, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 16, 2015
Association of HER2 codon 655 polymorphism with ovarian cancerRafał Watrowski, Dan Cacsire Castillo-Tong, Eva Schuster, et al.
Pageof 19